Tyrosine kinase inhibitors
The present invention relates to imidazo[1,2-a]pyrimidine derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
1 . A compound of Formula I:
or a pharmaceutically acceptable salt or stereoisomer thereof, wherein
a is independently 0 or 1;
b is independently 0 or 1;
m is independently 0, 1, or 2;
R 1 and R 3 are independently selected from:
1) hydrogen,
2) halogen and
3) C 1 -C 10 alkyl,
said alkyl optionally substituted with one to three substituents selected from R 6 ;
R 2 is selected from:
1) C 1 -C 10 alkyl,
2) aryl,
3) heterocyclyl, and
4) C 3 -C 8 cycloalkyl,
said alkyl, aryl, heterocyclyl and cycloalkyl optionally substituted with one, two or three substituents selected from R 6 ;
R 4 is selected from:
1) aryl,
2) heterocyclyl, and
3) C 3 -C 8 cycloalkyl,
said aryl, heterocyclyl and cycloalkyl optionally substituted with one, two or three substituents selected from R 6 ;
R 5 is selected from:
1) hydrogen,
2) NR 8 R 9 ,
3) halogen, and
4) C 1 -C 10 alkyl;
said alkyl optionally substituted with one to three substituents selected from R d ;
R 6 independently is:
1) (C═O) a O b C 1 -C 10 alkyl,
2) (C═O) a O b aryl,
3) C 2 -C 10 alkenyl,
4) C 2 -C 10 alkynyl,
5) (C═O) a O b heterocyclyl,
6) CO 2 H,
7) halo,
8) CN,
9) OH,
10) O b C 1 -C 6 perfluoroalkyl,
11) O a (C═O) b NR 8 R 9 ,
12) S(O) m R a ,
13) S(O) 2 NR 8 R 9 ,
14) oxo,
15) CHO,
16) (N═O)R 8 R 9 , or
17) (C═O) a O b C 3 -C 8 cycloalkyl,
said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one or more substituents selected from R 7 ;
R 7 is independently selected from:
1) (C═O) a O b (C 1 -C 10 )alkyl,
2) O b (C 1 -C 3 )perfluoroalkyl,
3) oxo,
4) OH,
5) halo,
6) CN,
7) (C 2 -C 10 )alkenyl,
8) (C 2 -C 10 )alkynyl,
9) (C═O) a O b (C 3 -C 6 )cycloalkyl,
10) (C═O) a O b (C 0 -C 6 )alkylene-aryl,
11) (C═O) a O b (C 0 -C 6 )alkylene-heterocyclyl,
12) (C═O) a O b (C 0 -C 6 )alkylene-N(R b ) 2 ,
13) C(O)R a ,
14) (C 0 -C 6 )alkylene-CO 2 R a ,
15) C(O)H,
16) (C 0 -C 6 )alkylene-CO 2 H, and
17) C(O)N(R b ) 2 ,
18) S(O) m R a , and
19) S(O) 2 NR 8 R 9 ;
said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heterocyclyl is optionally substituted with up to three substituents selected from R b , OH, (C 1 -C 6 )alkoxy, halogen, CO 2 H, CN, O(C═O)C 1 -C 6 alkyl, oxo, and N(R b ) 2 ; or
two R 7 s, attached to the same carbon atom are combined to form —(CH 2 ) u — wherein u is 3 to 6 and one or two of the carbon atoms is optionally replaced by a moiety selected from O, S(O) m , —N(R a )C(O)—, —N(R b )— and —N(COR a )—;
R 8 and R 9 are independently selected from:
1) H,
2) (C═O)O b C 1 -C 10 alkyl,
3) (C═O)O b C 3 -C 8 cycloalkyl,
4) (C═O)O b aryl,
5) (C═O)O b heterocyclyl,
6) C 1 -C 10 alkyl,
7) aryl,
8) C 2 -C 10 alkenyl,
9) C 2 -C 10 alkynyl,
10) heterocyclyl,
11) C 3 -C 8 cycloalkyl,
12) SO 2 R a , and
13) (C═O)NR b 2 ,
said alkyl, cycloalkyl, aryl, heterocylyl, alkenyl, and alkynyl is optionally substituted with one, two or three substituents selected from R 6 , or
R 8 and R 9 can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one, two or three substituents selected from R 7 ;
R a is independently selected from: (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, aryl, and heterocyclyl;
R b is independently selected from: H, (C 1 -C 6 )alkyl, aryl, heterocyclyl, (C 3 -C 6 )cycloalkyl, (C═O)OC 1 -C 6 alkyl, (C═O)C 1 -C 6 alkyl or S(O) 2 R a ; and
R d is independently selected from: unsubstituted or substituted aryl and unsubstituted or substituted heterocyclyl;
X is selected from: C 1 -C 6 alkylene, optionally substituted with one or two substituents selected from R 6 .
2 . The compound according to claim 1 of the Formula II:
or a pharmaceutically acceptable salt or stereoisomer thereof, wherein
a is independently 0 or 1;
b is independently 0 or 1;
m is independently 0, 1, or 2;
R 1 is selected from:
1) hydrogen,
2) halogen and
3) C 1 -C 10 alkyl,
said alkyl optionally substituted with one to three substituents selected from R 6 ; or
R 2 is selected from:
1) aryl,
2) heterocyclyl, and
3) C 3 -C 8 cycloalkyl,
said aryl, heterocyclyl and cycloalkyl optionally substituted with one, two or three substituents selected from R 6 ;
R 4 is selected from:
1) aryl, and
2) heterocyclyl,
said aryl and heterocyclyl optionally substituted with one, two or three substituents selected from R 6 ;
R 6 independently is:
1) (C═O) a O b C 1 -C 10 alkyl,
2) (C═O) a O b aryl,
3) C 2 -C 10 alkenyl,
4) C 2 -C 10 alkynyl,
5) (C═O) a O b heterocyclyl,
6) CO 2 H,
7) halo,
8) CN,
9) OH,
10) O b C 1 -C 6 perfluoroalkyl,
11) O a (C═O) b NR 8 R 9 ,
12) S(O) m R a ,
13) S(O) 2 NR 8 R 9 ,
14) oxo,
15) CHO,
16) (N═O)R 8 R 9 , or
17) (C═O) a O b C 3 -C 8 cycloalkyl,
said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one, two or three substituents selected from R 7 ;
R 7 is independently selected from:
1) (C═O) a O b (C 1 -C 10 )alkyl,
2) O b (C 1 -C 3 )perfluoroalkyl,
3) oxo,
4) OH,
5) halo,
6) CN,
7) (C 2 -C 10 )alkenyl,
8) (C 2 -C 10 )alkynyl,
9) (C═O) a O b (C 3 -C 6 )cycloalkyl,
10) (C═O) a O b (C 0 -C 6 )alkylene-aryl,
11) (C═O) a O b (C 0 -C 6 )alkylene-heterocyclyl,
12) (C═O) a O b (C 0 -C 6 )alkylene-N(R b ) 2 ,
13) C(O)R a ,
14) (C 0 -C 6 )alkylene-CO 2 R a ,
15) C(O)H,
16) (C 0 -C 6 )alkylene-CO 2 H, and
17) C(O)N(R b ) 2 ,
18) S(O) m R a , and
19) S(O) 2 NR 8 R 9 ;
said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heterocyclyl is optionally substituted with up to three substituents selected from R b , OH, (C 1 -C 6 )alkoxy, halogen, CO 2 H, CN, O(C═O)C 1 -C 6 alkyl, oxo, and N(R b ) 2 ; or
two R 7 s, attached to the same carbon atom are combined to form —(CH 2 ) u — wherein u is 3 to 6 and one or two of the carbon atoms is optionally replaced by a moiety selected from O, S(O) m , —N(R a )C(O)—, —N(R b )— and —N(COR a )—;
R 8 and R 9 are independently selected from:
1) H,
2) (C═O)O b C 1 -C 10 alkyl,
3) (C═O)O b C 3 -C 8 cycloalkyl,
4) (C═O)O b aryl,
5) (C═O)O b heterocyclyl,
6) C 1 -C 10 alkyl,
7) aryl,
8) C 2 -C 10 alkenyl,
9) C 2 -C 10 alkynyl,
10) heterocyclyl,
11) C 3 -C 8 cycloalkyl,
12) SO 2 R a , and
13) (C═O)NR b 2 ,
said alkyl, cycloalkyl, aryl, heterocylyl, alkenyl, and alkynyl is optionally substituted with one, two or three substituents selected from R 6 , or
R 8 and R 9 can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one, two or three substituents selected from R 7 ;
R a is independently selected from: (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, aryl, and heterocyclyl; and
R b is independently selected from: H, (C 1 -C 6 )alkyl, aryl, heterocyclyl, (C 3 -C 6 )cycloalkyl, (C═O)OC 1 -C 6 alkyl, (C═O)C 1 -C 6 alkyl and S(O) 2 R a ; and
R c and R c′ are independently selected from: H, OH, (C 1 -C 6 )alkyl, (C═O)OC 1 -C 6 alkyl, and (C═O)C 1 -C 6 alkyl; or R c and R c′ are combined to form oxo.
3 . The compound according to claim 2 of the Formula III:
or a pharmaceutically acceptable salt or stereoisomer thereof, wherein
a is independently 0 or 1;
b is independently 0 or 1;
m is independently 0, 1, or 2;
R 2 is selected from:
1) aryl,
2) heterocyclyl, and
3) C 3 -C 9 cycloalkyl,
said aryl, heterocyclyl and cycloalkyl optionally substituted with one, two or three substituents selected from R 6 ;
R 4 is selected from:
1) aryl, and
2) heterocyclyl,
said aryl and heterocyclyl optionally substituted with one, two or three substituents selected from R 6 ;
R 6 independently is:
1) (C═O) a O b C 1 -C 10 alkyl,
2) (C═O) a O b aryl,
3) C 2 -C 10 alkenyl,
4) C 2 -C 10 alkynyl,
5) (C═O) a O b heterocyclyl,
6) CO 2 H,
7) halo,
8) CN,
9) OH,
10) O b C 1 -C 6 perfluoroalkyl,
11) O a (C═O) b NR 8 R 9 ,
12) S(O) m R a ,
13) S(O) 2 NR 8 R 9 ,
14) oxo,
15) CHO,
16) (N═O)R 8 R 9 , or
17) (C═O) a O b C 3 -C 8 cycloalkyl,
said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one, two or three substituents selected from R 7 ;
R 7 is independently selected from:
1) (C═O) a O b (C 1 -C 10 )alkyl,
2) O b (C 1 -C 3 )perfluoroalkyl,
3) oxo,
4) OH,
5) halo,
6) CN,
7) (C 2 -C 10 )alkenyl,
8) (C 2 -C 10 )alkynyl,
9) (C═O) a O b (C 3 -C 6 )cycloalkyl,
10) (C═O) a O b (C 0 -C 6 )alkylene-aryl,
11) (C═O) a O b (C 0 -C 6 )alkylene-heterocyclyl,
12) (C═O) a O b (C 0 -C 6 )alkylene-N(R b ) 2 ,
13) C(O)R a ,
14) (C 0 -C 6 )alkylene-CO 2 R a ,
15) C(O)H,
16) (C 0 -C 6 )alkylene-CO 2 H, and
17) C(O)N(R b ) 2 ,
18) S(O) m R a , and
19) S(O) 2 NR 8 R 9 ;
said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heterocyclyl is optionally substituted with up to three substituents selected from R b , OH, (C 1 -C 6 )alkoxy, halogen, CO 2 H, CN, O(C═O)C 1 -C 6 alkyl, oxo, and N(R b ) 2 ;
R 8 and R 9 are independently selected from:
1) H,
2) (C═O)O b C 1 -C 10 alkyl,
3) (C═O)O b C 3 -C 8 cycloalkyl,
4) (C═O)O b aryl,
5) (C═O)O b heterocyclyl,
6) C 1 -C 10 alkyl,
7) aryl,
8) C 2 -C 10 alkenyl,
9) C 2 -C 10 alkynyl,
10) heterocyclyl,
11) C 3 -C 8 cycloalkyl,
12) SO 2 R a , and
13) (C═O)NR b 2 ,
said alkyl, cycloalkyl, aryl, heterocylyl, alkenyl, and alkynyl is optionally substituted with one, two or three substituents selected from R 6 , or
R 8 and R 9 can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one, two or three substituents selected from R 7 ;
R a is independently selected from: (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, aryl, and heterocyclyl; and
R b is independently selected from: H, (C 1 -C 6 )alkyl, aryl, heterocyclyl, (C 3 -C 6 )cycloalkyl, (C═O)OC 1 -C 6 alkyl, (C═O)C 1 -C 6 alkyl and S(O) 2 R a ; and
R c and R c′ are independently selected from: H, OH, (C 1 -C 6 )alkyl, (C═O)OC 1 -C 6 alkyl, and (C═O)C 1 -C 6 alkyl.
4 . A compound selected from:
Phenyl(6-phenylimidazo[1,2-α]pyrimidin-3-yl)methanone;
Phenyl(6-phenylimidazo[1,2-α]pyrimidin-3-yl)methanol;
3-(4-Methoxybenzyl)-6-phenylimidazo[1,2-α]pyrimidine;
3-(4-Hydroxybenzyl)-6-phenylimidazo[1,2-α]pyrimidine;
3-(4-Methoxybenzyl)-6-(3-thienyl)imidazo[1,2-α]pyrimidine;
3-(4-Hydroxybenzyl)-6-(3-thienyl)imidazo[1,2-α]pyrimidine;
3-(4-Methoxybenzyl)-6-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-α]pyrimidine;
3-(4-Hydroxybenzyl)-6-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-α]pyrimidine;
or a pharmaceutically acceptable salt or stereoisomer thereof.
5 . The compound according to claim 4 which is selected from:
3-(4-Hydroxybenzyl)-6-phenylimidazo[1,2-α]pyrimidinium trifluoroacetate;
3-(4-Hydroxybenzyl)-6-(3-thienyl)imidazo[1,2-α]pyrimidinium trifluoroacetate;
3-(4-Hydroxybenzyl)-6-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-α]pyrimidinium trifluoroacetate;
or stereoisomer thereof.
6 . A pharmaceutical composition that is comprised of a compound in accordance with claim 1 and a pharmaceutically acceptable carrier.
7 . A method of treating or preventing cancer in a mammal in need of such treatment that is comprised of administering to said mammal a therapeutically effective amount of a compound of claim 1 .
8 . A method of treating cancer or preventing cancer in accordance with claim 7 wherein the cancer is selected from cancers of the brain, genitourinary tract, lymphatic system, stomach, larynx and lung.
9 . A method of treating or preventing cancer in accordance with claim 7 wherein the cancer is selected from histiocytic lymphoma, lung adenocarcinoma, small cell lung cancers, pancreatic cancer, liver cancer, gastric cancer, colon cancer, multiple myeloma, glioblastomas and breast carcinoma.
10 . (canceled)
11 . (canceled)
12 . (canceled)
13 . (canceled)